Clinical Chemistry Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 48: 1375-1376, 2002;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (10)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Star, R.
Right arrow Articles by Hortin, G. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Star, R.
Right arrow Articles by Hortin, G. L.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2002;48:1375-1376.)
© 2002 American Association for Clinical Chemistry, Inc.

Editorial

New Markers for Kidney Disease

Robert Star1,2, Thomas Hostetter2 and Glen L. Hortin3a

1 Renal Diagnostics and Therapeutics Unit, and
2 Division of Kidney, Urologic, and Hematologic Diseases, National Institute for Diabetes and Digestive and Kidney Diseases, Bethesda, MD 20892

3 Department of Laboratory Medicine, Warren Magnusen Clinical Center, NIH, Bethesda, MD 20892

aAddress correspondence to this author at: Department of Laboratory Medicine, NIH, Bldg. 10, Room 2C-407, 10 Center Dr., Bethesda, MD 20892-1508. Fax 301-402-1885; e-mail ghortin@cc.nih.gov.

The first 20% of the full text of this article appears below.

There is ominous growth in chronic kidney disease among the US population, primarily related to type 2 diabetes (1). The current number of patients on dialysis (~300 000) is growing steadily as the prevalence of end-stage kidney disease grows geometrically with a doubling time of 10 years. The epidemic growth in diabetes, the leading cause of chronic kidney disease, portends continuation of this trend (2). Most patients with end-stage kidney disease will end up on dialysis because the supply of kidneys for transplants is limited to ~13 000 per year. A further warning sign from the National Health and Nutrition Examination survey is that an estimated 8 million Americans have a >=50% reduction of their glomerular filtration rate (GFR) (3). This group with impaired kidney function is at risk for progression to end-stage kidney disease as well as for development of cardiovascular disease.

One source of hope for stemming the dire trends in kidney disease is progress in the treatment of impaired kidney function, if it is detected and treated early (1)(2). A recent initiative, termed the National Kidney Disease Education Program, seeks to increase public awareness for preventive therapy. Increased awareness will create new demands on laboratories for early and more sensitive detection of kidney disease and for identification of new laboratory markers, such as one evaluated in this issue of the Journal (4). With the recent development of new genomic and proteomic approaches, there is also the potential for identification of many new markers requiring evaluation.

The laboratory marker that has long served as the mainstay for detecting impaired kidney function is serum creatinine. Unfortunately, serum creatinine is an insensitive marker of kidney injury. Two factors . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
 Nephrol Dial TransplantHome page
U. Poge, T. Gerhardt, A. Bokenkamp, B. Stoffel-Wagner, H.-U. Klehr, T. Sauerbruch, and R. P. Woitas
Time course of low molecular weight proteins in the early kidney transplantation period--influence of corticosteroids
Nephrol. Dial. Transplant., November 1, 2004; 19(11): 2858 - 2863.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
S. M. Hewitt, J. Dear, and R. A. Star
Discovery of Protein Biomarkers for Renal Diseases
J. Am. Soc. Nephrol., July 1, 2004; 15(7): 1677 - 1689.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
R. L. Mehta and G. M. Chertow
Acute Renal Failure Definitions and Classification: Time for Change?
J. Am. Soc. Nephrol., August 1, 2003; 14(8): 2178 - 2187.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
V. Jayagopal, B. G. Keevil, S. L. Atkin, P. E. Jennings, and E. S. Kilpatrick
Paradoxical Changes in Cystatin C and Serum Creatinine in Patients with Hypo- and Hyperthyroidism
Clin. Chem., April 1, 2003; 49(4): 680 - 681.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Association for Clinical Chemistry.